| fullrecord |
[{"key": "dc.contributor.advisor", "value": "Kuopio, Teijo", "language": "", "element": "contributor", "qualifier": "advisor", "schema": "dc"}, {"key": "dc.contributor.advisor", "value": "Ahtiainen, Maarit", "language": "", "element": "contributor", "qualifier": "advisor", "schema": "dc"}, {"key": "dc.contributor.author", "value": "Lehto, Niina", "language": "", "element": "contributor", "qualifier": "author", "schema": "dc"}, {"key": "dc.date.accessioned", "value": "2020-12-15T09:36:00Z", "language": null, "element": "date", "qualifier": "accessioned", "schema": "dc"}, {"key": "dc.date.available", "value": "2020-12-15T09:36:00Z", "language": null, "element": "date", "qualifier": "available", "schema": "dc"}, {"key": "dc.date.issued", "value": "2020", "language": "", "element": "date", "qualifier": "issued", "schema": "dc"}, {"key": "dc.identifier.uri", "value": "https://jyx.jyu.fi/handle/123456789/73209", "language": null, "element": "identifier", "qualifier": "uri", "schema": "dc"}, {"key": "dc.description.abstract", "value": "Kolmoisnegatiivinen rintasy\u00f6p\u00e4 (TNBC) kattaa 10\u201315 % kaikista rintasy\u00f6vist\u00e4.\nTNBC:ss\u00e4 kasvaimen soluissa ei ole hormonireseptoreita eik\u00e4 HER2-onkogeeni ole\nmonistunut, sairaus etenee nopeasti ja hoitovaihtoehtoja on v\u00e4h\u00e4n. T\u00e4m\u00e4n takia\nTNBC:n ennuste on huono. Ensimm\u00e4inen immunologinen l\u00e4\u00e4kevalmiste on\nhiljattain hyv\u00e4ksytty PD-L1-positiivisen TNBC:n hoitoon. L\u00e4\u00e4ke inhiboi PD-1/PDL1 reitti\u00e4 ja on parantanut huomattavasti TNBC-potilaiden selviytymist\u00e4. Kliiniseen\nk\u00e4ytt\u00f6\u00f6n on hyv\u00e4ksytty my\u00f6s immunohistokemiallinen (IHC) menetelm\u00e4, Ventana\nSP142, jonka avulla voidaan l\u00f6yt\u00e4\u00e4 t\u00e4st\u00e4 hoidosta mahdollisesti hy\u00f6tyv\u00e4t PD-L1-\npositiiviset TNBC-potilaat. T\u00e4ss\u00e4 ty\u00f6ss\u00e4 vertasimme kahta laboratoriossa kehitetty\u00e4\nPD-L1 IHC-menetelm\u00e4\u00e4 kaupalliseen Ventana SP142 menetelm\u00e4\u00e4n. M\u00e4\u00e4ritimme\nmy\u00f6s kasvainn\u00e4ytteist\u00e4 T-lymfosyyttien ja makrofagien m\u00e4\u00e4r\u00e4n sek\u00e4 selvitimme\nQuPath-sovelluksen mahdollisuuksia PD-L1:n m\u00e4\u00e4ritt\u00e4misess\u00e4. Aineistoon kuului\n113 TNBC-potilaan kasvainn\u00e4ytett\u00e4 Keski-Suomen Biopankista. Selvitimme my\u00f6s\nPD-L1-positiivisuuden ja tulehdussolum\u00e4\u00e4rien ennustemerkityst\u00e4 TNBC-potilailla.\nHuomasimme, ett\u00e4 tulehdussolujen PD-L1-positiivisuus erosi merkitt\u00e4v\u00e4sti\nmenetelmien v\u00e4lill\u00e4. Visuaalisen ja digitaalisen analyysin tulokset poikkesivat my\u00f6s\ntoisistaan. Tulehdussolujen suuri m\u00e4\u00e4r\u00e4 oli yhteydess\u00e4 TNBC-potilaiden\nparempaan ennusteeseen mutta PD-L1-positiivisuudella ei ollut vaikutusta.\nStandardin IHC-menetelm\u00e4n m\u00e4\u00e4ritt\u00e4minen sek\u00e4 hoidon spesifi kohdentaminen\nTNBC-potilailla vaatii lis\u00e4\u00e4 tutkimusta.", "language": "fi", "element": "description", "qualifier": "abstract", "schema": "dc"}, {"key": "dc.description.abstract", "value": "Triple-negative breast cancer (TNBC) accounts for 10-15% of all breast cancers.\nTNBC is negative for estrogen receptors, progesterone receptors, and the HER2 gene\nis not amplificated, grows fast but has only limited treatment options. Therefore,\nthe prognosis of TNBC is poor. The first immunotherapy medicine has recently been\napproved to treat PD-L1-positive TNBC. This drug has remarkably improved TNBC\npatient's survival inhibiting the PD-1/PD-L1 pathway that cancer utilizes. For\nselecting TNBC patients to receive this treatment, an immunohistochemical (IHC)\nmethod, Ventana SP142, has been approved for clinical use to detect PD-L1-\npositivity. In this study, we compared PD-L1 expression in immune cells between\ntwo laboratory developed PD-L1 IHC protocols and companion Ventana SP142,\ndetected the densities of T-lymphocytes and macrophages in tumor samples and\ntested the suitability of QuPath software for PD-L1 detection. The study material\nincluded tumor samples of 113 TNBC patients obtained from the Central Finland\nBiobank. Finally, we investigated the prognostic impact of PD-L1-positivity and\nimmune cell densities in TNBC patients. PD-L1-positivity in immune cells differed\nsignificantly between the protocols as well as between visual and digital analysis.\nPD-L1-positivity did not associate with the patient's prognosis. However, high\ndensities of immune cells were associated with better prognosis. The determination\nof a standard IHC method as well as the specific targeting of treatment in TNBC\npatients require further investigation.", "language": "en", "element": "description", "qualifier": "abstract", "schema": "dc"}, {"key": "dc.description.provenance", "value": "Submitted by Paivi Vuorio (paelvuor@jyu.fi) on 2020-12-15T09:36:00Z\nNo. of bitstreams: 0", "language": "en", "element": "description", "qualifier": "provenance", "schema": "dc"}, {"key": "dc.description.provenance", "value": "Made available in DSpace on 2020-12-15T09:36:00Z (GMT). No. of bitstreams: 0\n Previous issue date: 2020", "language": "en", "element": "description", "qualifier": "provenance", "schema": "dc"}, {"key": "dc.format.extent", "value": "52", "language": "", "element": "format", "qualifier": "extent", "schema": "dc"}, {"key": "dc.format.mimetype", "value": "application/pdf", "language": null, "element": "format", "qualifier": "mimetype", "schema": "dc"}, {"key": "dc.language.iso", "value": "eng", "language": null, "element": "language", "qualifier": "iso", "schema": "dc"}, {"key": "dc.rights", "value": "In Copyright", "language": "en", "element": "rights", "qualifier": null, "schema": "dc"}, {"key": "dc.title", "value": "Comparison of two laboratory developed PD-L1 assays with clinically approved Ventana SP142 assay and prognostic significance of PD-L1-positivity and immune cell densities in triple-negative breast cancer patients", "language": "", "element": "title", "qualifier": null, "schema": "dc"}, {"key": "dc.type", "value": "master thesis", "language": null, "element": "type", "qualifier": null, "schema": "dc"}, {"key": "dc.identifier.urn", "value": "URN:NBN:fi:jyu-202012157155", "language": "", "element": "identifier", "qualifier": "urn", "schema": "dc"}, {"key": "dc.type.ontasot", "value": "Pro gradu -tutkielma", "language": "fi", "element": "type", "qualifier": "ontasot", "schema": "dc"}, {"key": "dc.type.ontasot", "value": "Master\u2019s thesis", "language": "en", "element": "type", "qualifier": "ontasot", "schema": "dc"}, {"key": "dc.contributor.faculty", "value": "Matemaattis-luonnontieteellinen tiedekunta", "language": "fi", "element": "contributor", "qualifier": "faculty", "schema": "dc"}, {"key": "dc.contributor.faculty", "value": "Faculty of Sciences", "language": "en", "element": "contributor", "qualifier": "faculty", "schema": "dc"}, {"key": "dc.contributor.department", "value": "Bio- ja ymp\u00e4rist\u00f6tieteiden laitos", "language": "fi", "element": "contributor", "qualifier": "department", "schema": "dc"}, {"key": "dc.contributor.department", "value": "Department of Biological and Environmental Science", "language": "en", "element": "contributor", "qualifier": "department", "schema": "dc"}, {"key": "dc.contributor.organization", "value": "Jyv\u00e4skyl\u00e4n yliopisto", "language": "fi", "element": "contributor", "qualifier": "organization", "schema": "dc"}, {"key": "dc.contributor.organization", "value": "University of Jyv\u00e4skyl\u00e4", "language": "en", "element": "contributor", "qualifier": "organization", "schema": "dc"}, {"key": "dc.subject.discipline", "value": "Solu- ja molekyylibiologia", "language": "fi", "element": "subject", "qualifier": "discipline", "schema": "dc"}, {"key": "dc.subject.discipline", "value": "Cell and molecular biology", "language": "en", "element": "subject", "qualifier": "discipline", "schema": "dc"}, {"key": "yvv.contractresearch.funding", "value": "0", "language": "", "element": "contractresearch", "qualifier": "funding", "schema": "yvv"}, {"key": "dc.type.coar", "value": "http://purl.org/coar/resource_type/c_bdcc", "language": null, "element": "type", "qualifier": "coar", "schema": "dc"}, {"key": "dc.rights.accesslevel", "value": "restrictedAccess", "language": null, "element": "rights", "qualifier": "accesslevel", "schema": "dc"}, {"key": "dc.type.publication", "value": "masterThesis", "language": null, "element": "type", "qualifier": "publication", "schema": "dc"}, {"key": "dc.subject.oppiainekoodi", "value": "4013", "language": "", "element": "subject", "qualifier": "oppiainekoodi", "schema": "dc"}, {"key": "dc.subject.yso", "value": "rintasy\u00f6p\u00e4", "language": null, "element": "subject", "qualifier": "yso", "schema": "dc"}, {"key": "dc.subject.yso", "value": "rinnat", "language": null, "element": "subject", "qualifier": "yso", "schema": "dc"}, {"key": "dc.subject.yso", "value": "immuunij\u00e4rjestelm\u00e4", "language": null, "element": "subject", "qualifier": "yso", "schema": "dc"}, {"key": "dc.subject.yso", "value": "immunologia", "language": null, "element": "subject", "qualifier": "yso", "schema": "dc"}, {"key": "dc.subject.yso", "value": "diagnostiikka", "language": null, "element": "subject", "qualifier": "yso", "schema": "dc"}, {"key": "dc.subject.yso", "value": "breast cancer", "language": null, "element": "subject", "qualifier": "yso", "schema": "dc"}, {"key": "dc.subject.yso", "value": "breasts", "language": null, "element": "subject", "qualifier": "yso", "schema": "dc"}, {"key": "dc.subject.yso", "value": "immune system", "language": null, "element": "subject", "qualifier": "yso", "schema": "dc"}, {"key": "dc.subject.yso", "value": "immunology", "language": null, "element": "subject", "qualifier": "yso", "schema": "dc"}, {"key": "dc.subject.yso", "value": "diagnostics", "language": null, "element": "subject", "qualifier": "yso", "schema": "dc"}, {"key": "dc.format.content", "value": "fulltext", "language": null, "element": "format", "qualifier": "content", "schema": "dc"}, {"key": "dc.rights.url", "value": "https://rightsstatements.org/page/InC/1.0/", "language": null, "element": "rights", "qualifier": "url", "schema": "dc"}, {"key": "dc.rights.accessrights", "value": "The author has not given permission to make the work publicly available electronically. Therefore the material can be read only at the archival workstation at Jyv\u00e4skyl\u00e4 University Library (https://kirjasto.jyu.fi/en/workspaces/facilities).", "language": "en", "element": "rights", "qualifier": "accessrights", "schema": "dc"}, {"key": "dc.rights.accessrights", "value": "Tekij\u00e4 ei ole antanut lupaa avoimeen julkaisuun, joten aineisto on luettavissa vain Jyv\u00e4skyl\u00e4n yliopiston kirjaston arkistoty\u00f6semalta. Ks. https://kirjasto.jyu.fi/fi/tyoskentelytilat/laitteet-ja-tilat..", "language": "fi", "element": "rights", "qualifier": "accessrights", "schema": "dc"}, {"key": "dc.type.okm", "value": "G2", "language": null, "element": "type", "qualifier": "okm", "schema": "dc"}]
|